Horizon Kinetics Medical ETFMEDX
MEDX
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,158% more capital invested
Capital invested by funds: $5.67K [Q2] → $71.3K (+$65.6K) [Q3]
33% more funds holding
Funds holding: 3 [Q2] → 4 (+1) [Q3]
0.5% more ownership
Funds ownership: 0.04% [Q2] → 0.54% (+0.5%) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for MEDX.
Financial journalist opinion
Positive
Zacks Investment Research
7 months ago
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Positive
Zacks Investment Research
10 months ago
ETFs to Buy as Mounjaro Powers Eli Lilly's Q4 Earnings Beat
Eli Lilly and Company (LLY) posted robust fourth-quarter 2023 earnings, beating estimates on both the top and bottom lines driven by strong sales of its diabetes and weight-loss treatments.
Charts implemented using Lightweight Charts™